The rEVO Biologics strategic advisors are committed to ensuring that the company carries out its mission in developing and commercializing breakthrough treatments and making a real difference in the lives of patients. 

James A. Geraghty

Chairman of the Board
Entrepreneur in Residence, Third Rock Ventures

Read More

James A. Geraghty

Chairman of the Board
Entrepreneur in Residence, Third Rock Ventures

James Geraghty is currently an Entrepreneur in Residence at Third Rock Ventures in Boston and Chairman of Idera Pharmaceuticals (NASDAQ: IDRA). Prior to Third Rock Ventures, Mr. Geraghty served as Senior Vice President, North America strategy and business development, at Sanofi. Before Sanofi, he  spent 20 years at Genzyme Corporation, most recently as Senior Vice President and an Officer. While at Genzyme, his roles included, President of Genzyme Europe and General Manager of Genzyme's cardiovascular business. He also led strategic transactions that brought important new products into Genzyme. He served as a director of GTC Biotherapeutics (formerly Genzyme Transgenics Corporation), where he was Chairman, President and CEO. Mr. Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases program, under which Genzyme helped develop innovative therapeutic programs on a non-commercial basis. He served as co-chair of the executive committee for BIO 2007. A graduate of the Yale Law School, he has published articles in the Yale Law Journal, Health Affairs, and other publications. Mr. Geraghty holds an MS from the University of Pennsylvania and a BA from Georgetown University.

 

Denis Delval

Chairman and Chief Executive Officer, LFB S.A.

Read More

Denis Delval

Chairman and Chief Executive Officer, LFB S.A.

Denis Delval is a graduate of ESSEC and INSEAD business schools with a PhD in Pharmacy. He has a deep understanding of the pharmaceutical industry and has held important marketing, sales and strategic positions in France, Europe and worldwide and has managed international partnerships within various pharmaceutical groups (Bayer, Fournier Pharma, ALK). In 2006, he was appointed General Manager of ALK France. In 2012, he also became Senior Vice President of the Danish pharmaceutical company specialized in allergy immunotherapy treatments. He lectures at ESSEC business school and has also been Chairman of Lecrip.org, a healthcare think tank. Denis Delval was appointed Chairman and Chief Executive Officer of LFB S.A. in December of 2017.

Pamela W. McNamara

Co-Founder, Health Helm, Inc.

Read More

Pamela W. McNamara

Co-Founder, Health Helm, Inc.

Since 2011, Ms. McNamara has served as a co-founder of Health Helm, Inc. and an advisor on the faculty of the Hult International Business School and a consultant for the Center for Innovation, Excellence and Learning. From 2009 to 2011, Ms. McNamara served as the president of Cambridge Consultants, Inc.

Ms. McNamara served as the chief executive officer of CRF, Inc. from 2003 to 2008. Ms. McNamara served as chief executive officer of Arthur D. Little, Inc. from 2001 to February 2002, and as managing director of Arthur D. Little from 1997 to 2001, and as a partner of Arthur D. Little since 1992.

Ms. McNamara served the board of GTC Biotherapeutics, Inc. from 2002 to 2010. She currently serves as a member of the board of SouthCoast Health System and Hospitals Group, on the board of overseers of Tufts University School of Engineering and as a trustee of Brookhaven at Lexington. She holds a B.Sc. in civil engineering from Tufts University.

 

Jessica Hopfield, Ph.D.

Former Partner, McKinsey & Company

Read More

Jessica Hopfield, Ph.D.

Former Partner, McKinsey & Company

Jessica Hopfield is a former partner of McKinsey & Company in their Global Pharmaceutical practice. While at McKinsey from 1995-2009, she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy , R&D management and marketing.   She serves as Vice Chair of the Board Trustees of the Joslin Diabetes Center.  She is the President of J Hopfield Consulting which provides strategic guidance and executive coaching to start-up technology firms seeking to commercialize intellectual property.  Dr. Hopfield also held management positions at Merck Sharp and Dohme in Clinical Development, Outcomes Research, and Marketing.  She earned an MBA from Harvard Graduate School of Business Administration as a Baker Scholar, a PhD in neuroscience/biochemistry from the Rockefeller University, and a BS from Yale College.